ClinicalTrials.gg
RecruitingNCT07120386NPWT-NSTIUpdated Oct 23, 2026

Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections

An interventional study of Negative Pressure Wound Therapy and Negative Pressure Wound Therapy with Instillation in Necrotizing Soft Tissue Infections, sponsored by HealthPartners Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by HealthPartners Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies in Soft Tissue Infections with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Soft Tissue Infections · United States.

Planned enrollment
27th of 31
30 · median 160
Started
2025
the only one that year
No phase
12 of 39
4 open now
Registered
38th of 39
by date

Among the 39 studies in Soft Tissue Infections with a site in United States, this one is the 27th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2025, is one of 12 with no phase, and was the 38th registered.

Soft Tissue Infections

92 studies on the registry are indexed under Soft Tissue Infections; 14 are open to participants now.

Browse Soft Tissue Infections studies →

Open to participants now

5 of the 39 studies in Soft Tissue Infections with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Soft Tissue Infections studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Soft Tissue Infections with a site in United States, or all of them as a file.
02

Study summary

Necrotizing Soft Tissue Infections (NSTIs) are rapidly progressing infections that have a high morbidity and mortality, with the greatest morbidity related to managing the large wounds required to treat these patients. Initial treatment requires wide surgical removal of infected tissue and optimal management is essential to reducing morbidity in these patients. Negative pressure wound therapy (NPWT) is a widely used technology that has revolutionized wound management. NPWT is utilized across the spectrum of acute wounds, including routine postoperative incision management, traumatic wounds, and wounds related to surgical debridement of NSTIs which are frequently some of the most complicated of wounds encountered. Most NSTI cases at Regions Hospital currently utilize negative pressure wound therapy with instillation (NPWTi) where the wound is irrigated to clean out debris. Currently, there is a paucity of data comparing traditional NPWT and NPWTi and the choice of which device to use is left to surgeon discretion. This study is a first step at identifying the effects of NPWTi compared to NPWT alone on the care of NSTI patients. If the theoretical benefits of NPWTi over NPWT translate to practice, those treated with NPWTi would be expected to have a reduced rate of hospital readmission after their index hospitalization in addition to shorter time to definitive closure/coverage. This is a pilot study to assess the feasibility of enrolling patients with NSTIs in a randomized controlled trial to assess outcomes between the two devices.

03

Conditions studied

  • Necrotizing Soft Tissue Infections

Browse trials for

Keywords

  • Negative pressure wound therapy
  • NPWT
  • NPWTi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical suspicion for Necrotizing Soft Tissue Infection (NSTI) necessitating emergent operative intervention
  • Age >/=18 years old
  • Planned application of a negative pressure wound dressing

Exclusion criteria

Exclusion Criteria:

  • Patients who have a wound that does not allow for a wound vac
  • Patients receiving acute treatment for a NSTI at another institution
  • Incarcerated patients
  • Patients who do not survive to wound closure/coverage
  • Patients \<18 years old
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Negative Pressure Wound Therapy

    Patients in this arm will receive traditional Negative Pressure Wound Therapy (NPWT)

    Device: Negative Pressure Wound Therapy

  • Experimental
    Negative Pressure Wound Therapy with Instillation

    Patients in this arm will receive Negative Pressure Wound Therapy with Instillation of a hypochlorous acid solution (NPWTi)

    Device: Negative Pressure Wound Therapy with Instillation

Interventions

  • DeviceNegative Pressure Wound Therapy

    NPWT creates a vacuum seal over your wound to promote healing

    Also known as: NPWT

  • DeviceNegative Pressure Wound Therapy with Instillation

    NPWTi creates a vacuum seal over your wound and infuses the wound with hypochlorous acid (medical grade dilute bleach) to clean it.

    Also known as: NPWTi

06

What researchers measure

Primary outcomes

  1. Unplanned hospital readmission

    Did the patient have an unplanned readmission to the hospital (Y/N) within 30 days of discharge

    Time frame: Within 30 days of discharge

  2. Rate of healing

    Time from index debridement to final coverage in days

    Time frame: First operation and last operation

Other outcomes

  1. Number of operative interventions

    Number of times the patient required an operation related to their NSTI during their hospital stay

    Time frame: Through hospital discharge, median of 9 days

  2. Unplanned vac change

    Number of unplanned times the vacuum dressing had to be changed during their hospital stay

    Time frame: Through hospital discharge, median of 9 days

  3. Total vac changes

    Total number of times the vacuum dressing was changed (planned + unplanned) during their hospital stay

    Time frame: Through hospital discharge, median of 9 days

  4. Bleeding

    Bleeding at wound vac site (Y/N). During hospital stay

    Time frame: Through hospital discharge, median of 9 days

  5. Infection

    New infection at wound vac site (Y/N). During hospital stay

    Time frame: Through hospital discharge, median of 9 days

  6. Hospital length of stay

    Number of days spent in Hospital

    Time frame: At hospital discharge, median of 9 days

  7. Intensive Care Unit length of stay

    Number of days spent in the Intensive Care Unit

    Time frame: At hospital discharge, median of 9 days

  8. Floor length of stay

    Number of days spent inpatient in the hospital

    Time frame: At hospital discharge, median of 9 days

  9. Skilled Nursing Facility days

    Number of days spent in a skilled nursing facility

    Time frame: Up to 6 months after admission to skilled nursing facility

  10. Discharge disposition

    "Where was the patient discharged: ""1=Discharged/Transferred to a short-term general hospital for inpatient care 2=Discharged/Transferred to an Intermediate Care Facility (ICF) 3=Discharged/Transferred to home under care of organized home health service 4=Left against medical advice or discontinued care 5=Deceased/Expired 6=Discharged to home or self-care (routine discharge) 7=Discharged/Transferred to Skilled Nursing Facility (SNF) 8=Discharged/Transferred to hospice care 9=Discharged/Transferred to court/law enforcement. 10=Discharged/Transferred to inpatient rehab or designated unit 11=Discharged/Transferred to Long Term Care Hospital (LTCH) 12=Discharged/Transferred to a psychiatric hospital or psychiatric distinct part unit of a hospital 13=Discharged/Transferred to another type of institution not defined elsewhere"""

    Time frame: At hospital discharge, median of 9 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 14 interventional studies with no phase under Soft Tissue Infections, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 45. This study's planned 16 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Aug 2026 → Dec 2026 and completion Oct 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 13, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 2026was Aug 2026
CompletionEst.
Jan 2027was Oct 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Dec 2026
Oct 23, 2026
Study completion
Oct 2026→Jan 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Aug 2026→Dec 2026
    Study completion Oct 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07120386
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Aug 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Nicholas J Larson
Contact
RegionsSurgicalResearch@HealthPartners.com
651-254-4846
Brian S Myer, MD
principal investigator · Regions Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion